Nifoxipam (CAS: 74723-10-7) is a novel sedative-hypnotic drug that belongs to the benzodiazepine class, which is widely used for the treatment of anxiety and insomnia. The chemical name of Nifoxipam is 1-methyl-3-(2-thienyl)-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine. It has a molecular formula of C15H10N4O3S and a molecular weight of 342.33 g/mol.
CAS No:
The CAS number for Nifoxipam is 74723-10-7, which is assigned by the Chemical Abstracts Service, a division of the American Chemical Society.
Synonyms: 1-methyl-3-(2-thienyl)-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Health benefits of this product:
Nifoxipam is primarily used as a sedative-hypnotic for the treatment of anxiety and insomnia. It works by binding to gamma-aminobutyric acid (GABA) receptors in the brain, which enhances the inhibitory effects of GABA and reduces neuronal activity. This leads to a decrease in anxiety, muscle tension, and agitation, as well as an increase in drowsiness and sleep duration.
Potential effects:
The potential effects of Nifoxipam include:
Product mechanism:
Nifoxipam works by enhancing the inhibitory effects of GABA in the brain. GABA is the primary inhibitory neurotransmitter in the central nervous system, and it is responsible for reducing neuronal activity and promoting relaxation. Benzodiazepines like Nifoxipam bind to specific sites on GABA-A receptors, which increases the affinity of GABA for its receptor and enhances its inhibitory effects. This results in a reduction in anxiety, muscle tension, and agitation, as well as an increase in drowsiness and sleep duration.
Safety:
Nifoxipam is a potent sedative-hypnotic drug and should only be used under the supervision of a qualified healthcare provider. It can cause drowsiness, impaired coordination, and cognitive impairment, which may increase the risk of accidents or falls. Long-term use of benzodiazepines like Nifoxipam can also lead to dependence and withdrawal symptoms if discontinued abruptly. Therefore, it is important to use Nifoxipam as directed and to avoid alcohol and other sedatives while taking this medication.
Side effects:
The common side effects of Nifoxipam include drowsiness, dizziness, confusion, impaired coordination, and memory impairment. Less common side effects may include headache, nausea, vomiting, diarrhea, difficulty breathing, and allergic reactions. If you experience any of these side effects, you should contact your healthcare provider immediately.
Dosing information:
The recommended dose of Nifoxipam varies depending on the indication and individual patient factors. It is typically administered orally and should be taken with food to improve absorption. The usual starting dose for anxiety is 0.25–0.5 mg, taken 2–3 times per day. For insomnia, the recommended dose is 1–2 mg taken at bedtime. The maximum daily dose should not exceed 4 mg per day.
Conclusion:
Nifoxipam is a potent sedative-hypnotic drug that is primarily used for the treatment of anxiety and insomnia. It works by enhancing the inhibitory effects of GABA in the brain, leading to a decrease in anxiety, muscle tension, and agitation, as well as an increase in drowsiness and sleep duration. However, Nifoxipam can cause side effects such as drowsiness, impaired coordination, and cognitive impairment, and long-term use can lead to dependence and withdrawal symptoms
